- Home
- About
- Animal Owners
- Membership
- Services
- Contact us
< Back
Objectives:
To evaluate the efficacy and safety of tigilanol tiglate (TT) at 0.35mg/cm3 for intratumoural injection of nodular or fibroblastic sarcoids with up to 3 treatments.
Methods:
Open, non-controlled and non-blinded treatment trial including six university and two private clinics (March 2021 to November 2022). In eligible tumours diagnosis was confirmed by histologic examination; tumour volume was limited (0.3 to 6 cm3) and the maximum cumulative TT dose at any one intervention predetermined (2 mg). Short and long-term treatment success was defined as complete tumour regression and absence of recurrence at veterinary follow-up examination, 84 days and a minimum of 6 months post last treatment, respectively. Potential determinants of complete regression were explored using multilevel logistic regression, lowless plots and fractional polynomial regression.
Results:
41 sarcoids (30 horses) were eligible for analysis. Periorbital and nodular naïve sarcoids predominated. In 2/30 horses a serious adverse event was reported requiring additional veterinary management. In the short term, a single intratumoural injection resulted in regression in 56% of tumours (23/41) and up to three treatments increased regression rate to 73% (30/41). For successfully treated sites with follow up data all remained tumour free at 6 (25 sarcoids) and 12 months post last treatment (23 sarcoids).
Sarcoid type, location and number/horse did not affect short-term outcome. Odds of a successful outcome were dependent on tumour volume and decreased by a factor of 0.6 (95% CI 0.3 to 1.0; P=0.039) for each 1 cm3 increase.
Conclusions:
TT at 0.35mg/cm3 is an effective and safe treatment for nodular/fibroblastic sarcoids.
34th Annual Scientific Meeting proceedings
Stream:
|
Session:
Date/Time: 30-11--0001 (00:00 - 00:00) | Location:
Date/Time: 30-11--0001 (00:00 - 00:00) | Location:
Safety and Efficacy of Intratumoural Tigilanol Tiglate (Stelfonta®) in the treatment of equine sarcoids: Outcome of an international treatment trial
Labens R*1, Saba C2, Williams J*2, Hollis A3, Ensink J*4, José Cunilleras E5, Jordana Garcia M*5, Bergvall K6, Ruppin M7, Condon F7, Spelta C8, McGee C9, De Ridder T9, Reddell P9
1Charles Sturt University, Wagga Wagga, Australia, 2University of Georgia, Athens, USA, 3University of Cambridge, Cambridge, United Kingdom, 4Utrecht University, Utrecht, Netherlands, 5Universitat Autònoma de Barcelona, Barcelona, Spain, 6Swedish University of Agricultural Sciences, Uppsala, Sweden, 7Tableland Veterinary Service, Malanda, Australia, 8Apiam Animal Health, Clermont, Australia, 9Qbiotics Group, Brisbane, Australia.
Objectives:
To evaluate the efficacy and safety of tigilanol tiglate (TT) at 0.35mg/cm3 for intratumoural injection of nodular or fibroblastic sarcoids with up to 3 treatments.
Methods:
Open, non-controlled and non-blinded treatment trial including six university and two private clinics (March 2021 to November 2022). In eligible tumours diagnosis was confirmed by histologic examination; tumour volume was limited (0.3 to 6 cm3) and the maximum cumulative TT dose at any one intervention predetermined (2 mg). Short and long-term treatment success was defined as complete tumour regression and absence of recurrence at veterinary follow-up examination, 84 days and a minimum of 6 months post last treatment, respectively. Potential determinants of complete regression were explored using multilevel logistic regression, lowless plots and fractional polynomial regression.
Results:
41 sarcoids (30 horses) were eligible for analysis. Periorbital and nodular naïve sarcoids predominated. In 2/30 horses a serious adverse event was reported requiring additional veterinary management. In the short term, a single intratumoural injection resulted in regression in 56% of tumours (23/41) and up to three treatments increased regression rate to 73% (30/41). For successfully treated sites with follow up data all remained tumour free at 6 (25 sarcoids) and 12 months post last treatment (23 sarcoids).
Sarcoid type, location and number/horse did not affect short-term outcome. Odds of a successful outcome were dependent on tumour volume and decreased by a factor of 0.6 (95% CI 0.3 to 1.0; P=0.039) for each 1 cm3 increase.
Conclusions:
TT at 0.35mg/cm3 is an effective and safe treatment for nodular/fibroblastic sarcoids.
This website uses cookies to improve your experience and for traffic analysis. If you continue, we’ll assume that you agree to the use of cookies as stated in our Cookie Policy.